Literature DB >> 29264362

Airway microbiome research: a modern perspective on surveillance cultures?

Damien Roux1, Pouline M van Oort2, Jean-Damien Ricard1, Lieuwe D J Bos2.   

Abstract

The incidence of ventilator-associated pneumonia (VAP) is estimated to be around 10% in a high-risk population. Over the last decade, major improvements have been made in the prevention of VAP, with great cost-effectiveness. However, we still do not understand the exact pathogenesis of VAP. A better understanding might explain why some patients develop ventilator-associated tracheobronchitis, while others develop VAP even though they are infected with the same types of pathogens. Microbiome research has been a hot topic in translational medicine over the past decade. Slowly, microbiome research has also been introduced to the intensive care setting. One of the areas where it may influence our pathophysiological considerations is in VAP. The adapted island has been proposed for the colonization and infection of the respiratory tract. In this model, not only the immigration of bacteria into the lung is important, but elimination and regional growth factors are of equal significance. The importance of these factors can be supported by epidemiological studies. Several small observational studies on the development of the pulmonary microbiome during mechanical ventilation also support this theory. We speculate on the consequences of the newest insights in microbiome research on the prevention and targeted treatment of VAP. We conclude that there is still a strong need for more in-depth analyses of the changes in the microbial composition of the pulmonary microbiome during mechanical ventilation and with the development of VAP.

Entities:  

Keywords:  Ventilator-associated pneumonia (VAP); microbiome; prevention

Year:  2017        PMID: 29264362      PMCID: PMC5721213          DOI: 10.21037/atm.2017.08.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  45 in total

1.  Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update.

Authors:  Michael Klompas; Richard Branson; Eric C Eichenwald; Linda R Greene; Michael D Howell; Grace Lee; Shelley S Magill; Lisa L Maragakis; Gregory P Priebe; Kathleen Speck; Deborah S Yokoe; Sean M Berenholtz
Journal:  Infect Control Hosp Epidemiol       Date:  2014-09       Impact factor: 3.254

2.  Is a strategy based on routine endotracheal cultures the best way to prescribe antibiotics in ventilator-associated pneumonia?

Authors:  Carlos M Luna; Sergio Sarquis; Michael S Niederman; Fernando A Sosa; Maria Otaola; Nicolas Bailleau; Carlos A Vay; Angela Famiglietti; Célica Irrazabal; Abelardo A Capdevila
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

3.  Ten ineffective interventions to prevent ventilator-associated pneumonia.

Authors:  Demosthenes Makris; Carlos Luna; Saad Nseir
Journal:  Intensive Care Med       Date:  2017-05-03       Impact factor: 17.440

4.  Lung microbiome dynamics in COPD exacerbations.

Authors:  Zhang Wang; Mona Bafadhel; Koirobi Haldar; Aaron Spivak; David Mayhew; Bruce E Miller; Ruth Tal-Singer; Sebastian L Johnston; Mohammadali Yavari Ramsheh; Michael R Barer; Christopher E Brightling; James R Brown
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

5.  Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia.

Authors:  Thomas P Hellyer; Andrew Conway Morris; Daniel F McAuley; Timothy S Walsh; Niall H Anderson; Suveer Singh; Paul Dark; Alistair I Roy; Simon V Baudouin; Stephen E Wright; Gavin D Perkins; Kallirroi Kefala; Melinda Jeffels; Ronan McMullan; Cecilia M O'Kane; Craig Spencer; Shondipon Laha; Nicole Robin; Savita Gossain; Kate Gould; Marie-Hélène Ruchaud-Sparagano; Jonathan Scott; Emma M Browne; James G MacFarlane; Sarah Wiscombe; John D Widdrington; Ian Dimmick; Ian F Laurenson; Frans Nauwelaers; A John Simpson
Journal:  Thorax       Date:  2014-10-08       Impact factor: 9.102

6.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.

Authors:  Leopoldo N Segal; Jose C Clemente; Benjamin G Wu; William R Wikoff; Zhan Gao; Yonghua Li; Jane P Ko; William N Rom; Martin J Blaser; Michael D Weiden
Journal:  Thorax       Date:  2016-08-02       Impact factor: 9.139

Review 7.  Ventilator-associated pneumonia: present understanding and ongoing debates.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Intensive Care Med       Date:  2014-11-27       Impact factor: 17.440

8.  Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data.

Authors:  Yan Wei Lim; Robert Schmieder; Matthew Haynes; Mike Furlan; T David Matthews; Katrine Whiteson; Stephen J Poole; Christopher S Hayes; David A Low; Heather Maughan; Robert Edwards; Douglas Conrad; Forest Rohwer
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

9.  Chapter 12: Human microbiome analysis.

Authors:  Xochitl C Morgan; Curtis Huttenhower
Journal:  PLoS Comput Biol       Date:  2012-12-27       Impact factor: 4.475

10.  Functional Metagenomics of the Bronchial Microbiome in COPD.

Authors:  Laura Millares; Vicente Pérez-Brocal; Rafaela Ferrari; Miguel Gallego; Xavier Pomares; Marian García-Núñez; Concepción Montón; Silvia Capilla; Eduard Monsó; Andrés Moya
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  2 in total

1.  Changes in lung microbiome do not explain the development of ventilator-associated pneumonia.

Authors:  Lieuwe D J Bos; Andre C Kalil
Journal:  Intensive Care Med       Date:  2019-07-17       Impact factor: 17.440

Review 2.  Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

Authors:  Laia Fernández-Barat; Ruben López-Aladid; Antoni Torres
Journal:  EBioMedicine       Date:  2020-09-16       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.